Clonal evolution with + 11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib

References

• Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J, Canaani E, Arlinghaus R. Tyrosine phosphorylation of p160 BCR by p 210 BCR—ABL. Blood 1993;82:1257.
   PubMed Web of Science ®Google Scholar
• Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998;91:3995–4019.
   PubMed Web of Science ®Google Scholar
• Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer RE, Bloomfield CD. Clinical significance of the BCR—ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762). Blood 1992;80: 2983.
   PubMed Web of Science ®Google Scholar
• Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood 2006;, December 14; [in press Epub ahead of print].
   Google Scholar
• Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphia-chromosome positive adult acute lympho-cytic leukemia: Characteristics, treatment results, and prog-nosis in 41 patients. Am J Med 1994;97:60.
   PubMed Web of Science ®Google Scholar
• Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995;85(5): 1151–1168.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Evans WE. Drug Therapy: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166–178.
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R. Japan Adult Leukemia Study Group. High complete remission rate and promising outcome by combi-nation of imatinib and chemotherapy for newly diagnosed BCR—ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Chin Oncol 2006;24(3):460–466.
   Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhauser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufman M, Binckebanck A, Bruck P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood 2006; 108(5):1469–1477.
   Google Scholar
• Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR—ABL-positive acute lymphoblastic leukemia. Blood 2004;104 (12) :3507–3512.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Meloni G, Chiarenza A, Malagola M, Fabbiano F, Recchia A, Kropp MG, Offidani M, Palmieri S, Cilloni D, Torelli G, Cimino G, Foâ R, Baccarani M, Mandelli F. Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph + ALL patients: Results of the GIMEMA prospective study LAL0201 [abstract]. Blood 2004;104?:2739, 104. Abstr. 2739 OR Blood (ASH Annual Meeting Abstracts).
   PubMed Web of Science ®Google Scholar
• Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with second-ary chromosomal aberrations. Chin Cancer Res 2003;9(4): 1333–1337.
   Web of Science ®Google Scholar
• Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative meta-phases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98(9):1905–1911.
   Google Scholar
• Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian H1\4. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101 (10):3794–3800.
   Google Scholar
• Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E. Leading prognostic relevance of the BCR—ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536–1543.
   Google Scholar
• Dombret H, Gabert J, Boiron JM, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P, Bourhis JH, Fegueux N, Charm in C, Boucheix C, Lhéritier V, Espérou H, MacIntyre E, Vernant JP, Fière D. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood 2002;100: 2357–2366.
   PubMed Web of Science ®Google Scholar
• Martin TG, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Advances in the treatment of adult acute lymphocytic leukemia. Hematol Oncol Chin North Am 2001;15:97–120.
   Google Scholar
• O'Brien S, Thomas D, Cortes J, Faderl S, Giles F, Pierce S, Shan J, Ferrajoli A, Keating M, Kantarjian H. Long-term follow-up results of hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL) ASCO Meeting Abstracts July 15 2004. p 6539
   Google Scholar
• Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leuke-mia with hyper-CVAD and imatinib mesylate. Blood 2004; 103:4396–4407.
   Google Scholar
• De Labarthe A, Rousselot P, Huquet-Rigal F, Delabesse E, Witz F, Maury S, Rea D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lheritier V, Vernant JP, Thomas X, Ifrah N, Dombret H. Imatinib combined with induction or consolida-tion chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the GRAAPH-2003 study. Blood 2007;109 (4): 1408–1413.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR—ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344: 1038–1042.
   PubMed Web of Science ®Google Scholar
• Marktel S, Bua M, Mann D, Chase A, Caroline U, Armstrong L, Apperley JF, Olavarria E, Goldman JM. Emergence of additional chromosomal abnormalities following treatment with 5TI571 (imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase. (abstract) Blood 2001;98:617a.
   Web of Science ®Google Scholar
• Hoser G, Majsterek I, Romana DL, Slupianek A, Blasiak J, Skorski T. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: Role in drug resistance? Leuk Res 2003;27(3):267–273.
   PubMed Web of Science ®Google Scholar
• Hui AB, Or YY, Takano H, Tsang RK, To KF, Guan XY, Sham JS, Hung KW, Lam CN, van Hasselt CA, Kuo WL, Gray JW, Huang DP, Lo KW. Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 2005;65(18):8125–8133.
   Google Scholar
• Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003;78(3):323–335.
   PubMed Web of Science ®Google Scholar
• Schraml P, Schwerdtfeger G, Burkhalter F. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5;q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003;163(3): 985–992.
   Google Scholar
• Poppe B, Vandesompele J, Schoch C, Lindvall C, Mrózek K, Bloomfield CD, Beverloo HB, Michaux L, Dastugue N, Herens C, Yigit N, Paepe AD, Hagemeijer A, and Speleman F. Expression analyses identity MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood 2004;103(1): 229–235.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Charm in C, Magaud JP, Campos L, Thomas X, Fiere D, Rimokh R. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly: confirmation of the existence of different entities with 11q23 breakpoint. Leukemia 1998;12(1):25–33.
   PubMed Web of Science ®Google Scholar
• Ishizawa S, Slovak ML, Popplewell L, Bedell V, Wrede JE, Carter NH, Snyder DS, Arber DA. High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities. Leukemia 2003;17(6): 1091–1095.
   PubMed Web of Science ®Google Scholar
• Shah N, Sawyers CL, Kantarjian H, Donato N, Nicoll J, Cortes J, Paquette R, Huang F, Clark E, Talpaz M. Correlation of clinical response to BMS-354825 with BCR—ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromo-some-associated acute lymphoblastic leukemia (Ph ± ALL) ASCO Meeting Abstracts June 1 2005. p 6521
   Google Scholar
• Coutre S, Martinelli G, Dombret H, Hochhaus A, Larson R, Saglio G, Gollerkeri A, Apanovitch A, Ottman OG. Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph ± ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 "START-L" study ASCO Meeting Abstracts June 20 2006. p 6528
   Google Scholar